China's new crown vaccine research and development "accelerated run" is expected to be available by the end of this year

china to accelerate research and development of the new crown vaccine. Two Chinese companies producing inactivated vaccines for the new coronavirus said in Beijing on Wednesday that they were pushing ahead with phase III clinical trials of the vaccine, which are expected to be available by the end of the year.Since the outbreak of neo-corona pneumonia, China has adhered to five technical routes of inactivated vaccine, nucleic acid vaccine, recombinant protein vaccine, adenovirus vector vaccine and detoxifying influenza virus vector vaccine to improve the efficiency of vaccine research and development.Not only in China, but also in the research and development of new crown vaccines. China's Centers for Disease Control and Prevention experts said on the 21st, the world has 29 vaccines into clinical trials, 138 vaccines in preclinical research. Data from the World Health Organization show that six vaccines are in Phase III clinical trials, three of them from China.“ At present, China's bio-new coronavirus inactivated vaccine has been launched in the United Arab Emirates, Peru, Morocco and other places. Zhang Yuntao, vice president of China Biotechnology Co., Ltd., said the company is pushing ahead with phase III clinical studies overseas, "and we hope, or have a good chance, of going public by the end of the year".Compared with traditional vaccine research and development, the new crown vaccine research and development is much faster. In this regard, Zhang Yuntao said, this is due to inactivated vaccines in the early stage has formed a very good accumulation of technology, including system research, quality control and so on.He revealed that the company in Beijing, Wuhan, two research institutes of the new crown vaccine production workshop put into use, the annual output will reach a total of 220 million doses.Vaccines are seen as the "killer" in the fight against the new crown pneumonia epidemic, and people around the world are looking forward to it. Yu Weidong, chairman, president and CEO of Kexing Holding Biotechnology Co., Ltd., which develops the new coronavirus inactivated vaccine " Kellefort", said that phase III clinical trials are being launched in Brazil, Indonesia and other countries. Among them, Kelleford received clinical research approval from the Indonesian Drug Administration in July and launched Phase III Clinical Entry in The City of Wanlong, West Java, in August;“ It is expected to go on sale by the end of this year. Yan Weidong said that Koxing Holding Biotechnology Co., Ltd.'s Beijing Koxing Zhongwei Biotechnology Co., Ltd. started the construction project of industrialization of the new coronavirus inactivated vaccine at the end of March this year, and the 70,000 square meters vaccine plant located in Daxing District of Beijing will be put into trial production by the end of August, which will produce more than 300 million doses per year.China has made a clear commitment to be a global public product after the successful development of its new crown vaccine. So what is the future market pricing for the new crown vaccine? In this regard, Yan Weidong said that the new crown vaccine is a public health product, to consider its accessability, "will strive to make China's vaccine market as soon as possible, so that the general public as soon as possible to benefit." (China News Network)